Core Viewpoint - Dongxing Medical plans to acquire 90% equity of Wuhan Yijiaobao, which is expected to constitute a major asset restructuring [2][7]. Group 1: Acquisition Details - On September 26, Dongxing Medical signed a "Share Acquisition Intent Agreement" with all shareholders of Wuhan Yijiaobao to purchase 90% of its equity for cash [7]. - The final transaction price will be based on an evaluation report from a qualified asset appraisal agency as per the Securities Law of the People's Republic of China [11]. - A exclusivity period is established from the signing of the agreement until May 31, 2026, during which the current shareholders cannot negotiate with other parties regarding the equity transfer [12]. Group 2: Strategic Rationale - The acquisition aligns with Dongxing Medical's business development strategy and aims to integrate high-quality industry resources, extending its surgical medical device supply chain and actively expanding into the synthetic biology field [14]. - Wuhan Yijiaobao specializes in the research, production, and sales of high-end orthopedic and biomedical materials, holding multiple medical device registration certificates [14][16]. Group 3: Financial Performance - Dongxing Medical's main business has shown a declining trend since its listing on the Shenzhen Stock Exchange on November 30, 2022 [18]. - From 2021 to 2024, the company's net profit after deducting non-recurring gains and losses has decreased from 1.03 billion to approximately 66.46 million [19]. - In the first half of 2025, Dongxing Medical reported a 14.17% year-on-year decline in revenue to 183.29 million, and a 36.47% drop in net profit to 30.29 million [22].
301290，重大资产重组！